IDEAYA Biosciences, Inc. $IDYA Shares Sold by Rafferty Asset Management LLC

Rafferty Asset Management LLC cut its stake in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) by 15.2% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 93,152 shares of the company’s stock after selling 16,655 shares during the quarter. Rafferty Asset Management LLC owned about 0.11% of IDEAYA Biosciences worth $2,535,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in the stock. Aster Capital Management DIFC Ltd purchased a new stake in IDEAYA Biosciences during the third quarter worth about $38,000. Abich Financial Wealth Management LLC acquired a new stake in shares of IDEAYA Biosciences during the 3rd quarter valued at approximately $58,000. Elevation Point Wealth Partners LLC acquired a new stake in shares of IDEAYA Biosciences in the 2nd quarter worth approximately $61,000. Daiwa Securities Group Inc. grew its holdings in shares of IDEAYA Biosciences by 16.1% in the 2nd quarter. Daiwa Securities Group Inc. now owns 3,141 shares of the company’s stock worth $66,000 after acquiring an additional 436 shares during the period. Finally, PNC Financial Services Group Inc. increased its stake in IDEAYA Biosciences by 39.1% in the 2nd quarter. PNC Financial Services Group Inc. now owns 3,344 shares of the company’s stock valued at $70,000 after purchasing an additional 940 shares in the last quarter. Hedge funds and other institutional investors own 98.29% of the company’s stock.

Analyst Upgrades and Downgrades

IDYA has been the topic of a number of research analyst reports. Guggenheim reiterated a “buy” rating and set a $50.00 target price on shares of IDEAYA Biosciences in a research report on Wednesday, February 18th. UBS Group assumed coverage on shares of IDEAYA Biosciences in a research note on Wednesday, January 7th. They issued a “buy” rating and a $50.00 price objective on the stock. Citigroup lifted their target price on shares of IDEAYA Biosciences from $64.00 to $65.00 and gave the stock a “buy” rating in a research report on Thursday, February 19th. Truist Financial increased their price target on shares of IDEAYA Biosciences from $59.00 to $60.00 and gave the company a “buy” rating in a research report on Tuesday, January 6th. Finally, Wedbush raised their price objective on shares of IDEAYA Biosciences from $49.00 to $52.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 18th. Fifteen research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, IDEAYA Biosciences currently has a consensus rating of “Moderate Buy” and an average target price of $48.69.

Insider Activity

In other IDEAYA Biosciences news, Director Jeffrey Stein bought 50,000 shares of the company’s stock in a transaction that occurred on Monday, March 2nd. The stock was purchased at an average cost of $32.96 per share, for a total transaction of $1,648,000.00. Following the completion of the purchase, the director owned 54,281 shares of the company’s stock, valued at $1,789,101.76. This trade represents a 1,167.95% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 2.50% of the stock is owned by company insiders.

IDEAYA Biosciences Price Performance

Shares of NASDAQ IDYA opened at $34.68 on Thursday. The company has a 50-day simple moving average of $33.95 and a 200-day simple moving average of $31.07. The company has a market cap of $3.05 billion, a PE ratio of -26.47 and a beta of 0.09. IDEAYA Biosciences, Inc. has a 12 month low of $13.45 and a 12 month high of $39.28.

IDEAYA Biosciences (NASDAQ:IDYA) last announced its earnings results on Tuesday, February 17th. The company reported ($0.94) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.03) by $0.09. The firm had revenue of $21.75 million for the quarter, compared to analyst estimates of $5.95 million. The firm’s revenue was up 55.7% compared to the same quarter last year. During the same quarter last year, the business posted ($1.49) EPS. On average, analysts anticipate that IDEAYA Biosciences, Inc. will post -3.07 EPS for the current year.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences is a clinical-stage precision oncology company dedicated to the discovery and development of novel therapies that exploit synthetic lethality in cancer cells. By targeting key DNA damage response pathways, the company aims to selectively kill tumor cells exhibiting specific genetic vulnerabilities while sparing healthy tissue. IDEAYA’s pipeline includes small-molecule inhibitors designed to address underserved tumor types, and its lead programs are advancing through Phase 1 and Phase 2 clinical trials in multiple oncology indications.

Central to IDEAYA’s approach is its Modular Approach to Precision (MAP) platform, which integrates proprietary genomic and functional screening technologies to identify critical cancer-specific dependencies.